Nir Barzilai at ARDD2025: From Pathways to Patients: Translating Geroscience into Gerotherapeutics

Value of the Information & Strength of the Argument

The talk provides valuable insights into the potential of repurposing existing drugs for aging, supported by specific clinical trial data. Barzilai’s argumentation is coherent, moving from preclinical evidence to clinical outcomes, and he addresses potential challenges such as the need for biomarkers and the timing of intervention. However, the evidence is selectively presented, and he does not delve into potential adverse effects or limitations of the discussed drugs.

Scientific Rigor, Source Quality, Title Accuracy

Barzilai references several clinical trials and studies, including the ITP (Interventions Testing Program) and trials on SGLT2 inhibitors, metformin, and GLP-1 agonists. He mentions the DPP trial for metformin and the COVID-19 metformin trial. The title accurately reflects the content. The presentation is based on expert opinion and published data, but specific citations are not provided in the video.

The title accurately reflects the content, focusing on translating geroscience into gerotherapeutics.

8/10

Presentation by a leading expert in geroscience, referencing specific clinical trials and data, but largely based on expert opinion and selective evidence without full methodological detail.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction to aging research and the functional definition of aging.
• 03:00Discussion on the importance of FDA-approved drugs and repurposing for aging.
• 07:00Criteria for gerotherapeutics: targeting hallmarks of aging and clinical evidence.
• 10:00Presentation of data on SGLT2 inhibitors and their effects on kidney disease, cardiovascular disease, and mortality.
• 13:00Discussion on the effects of metformin, bisphosphonates, and GLP-1 on various outcomes.
• 15:00Legal aspects of repurposing FDA-approved drugs and examples of repurposing.
• 18:00Implementation strategies: secondary prevention, starting age, and drug selection.
• 20:00Need for biomarkers that change within months and the ARPA-H initiative.
• 22:00Q&A session on bisphosphonates and timing of intervention.

• Interventions Testing Program (ITP) — Mentioned as a source of lifespan data for SGLT2 inhibitors in mice.
• DPP trial (Diabetes Prevention Program) — Referenced for metformin's effect on prediabetes.
• Metformin and COVID-19 trial — Mentioned for metformin's effect on COVID-19 outcomes.

• Interventions Testing Program (ITP) — Supports the claim that SGLT2 inhibitors extend lifespan in female mice.
• Metformin and COVID-19 trial — Supports the claim that metformin reduces hospitalization and mortality in COVID-19.

• Rapamycin and healthspan — Barzilai notes that rapamycin failed a phase 3 trial for immune healthspan, indicating a lack of clinical evidence for its use as a gerotherapeutic.